Several new drugs have been on the stage of hepatitis B market and disputes

        China 120 million hepatitis B virus carriers, 30 million patients with chronic hepatitis B, hepatitis B treatment costs each year for more than 300 billion yuan, such a huge market has long been regarded as the domestic and foreign manufacturers a hotly contested spot. Had been Glaxo's lamivudine hepatitis B drug China dominate the market, with the domestic and foreign "A Duff Vee ester" at loggerheads were four, and entecavir etc. some new drugs have been on stage, makes the market competition intensified.

A weakness of lamivudine resistance

        Chronic hepatitis B requires long-term treatment, but there has been a lack of accurate and safe long-term therapeutic drug. GlaxoSmithKline Co listed in 1999 (15.8 yuan / lamivudine tablets), with its convenient, short-term, oral antiviral efficacy of good advantage, become the best selling prescription drugs for hepatitis B in a few years, and has been implemented in Chinese local production. According to estimates, the current terminal sales in China lamivudine reached 1 billion yuan, GlaxoSmithKline also boarded the field of prescription drugs in the treatment of chronic hepatitis B toubajiaoyi.

        However, to lamivudine GlaxoSmithKline's good times don't last long. The drug patent protection expires in 2006; in addition, lamivudine in patients with long-term use, the virus mutation, drug resistance and disease progression to this phenomenon, GlaxoSmithKline in Chengdu, Beijing, Shanghai, Hangzhou and other areas to a series of lawsuits. Therefore, as soon as possible, as soon as possible to the listing of second new drugs to keep the market share of its magic weapon. In September 6th, GlaxoSmithKline in Beijing, Shanghai, Guangzhou, Chengdu four held a press conference, announced that "the second generation of nucleoside drugs in the" comprehensive listing in Chinese.

The two advantage of adefovir dipivoxil "indicates its market prospects: after long-term use, the virus mutation rate is low; and for taking lamivudine and hepatitis B virus can cause the variability. GSK plan: mutation in patients resistant to lamivudine, adefovir dipivoxil is a new virus, the choice of first-line drugs. This will not only solve the potential contradictions between the two, but also to expand the market.

"Domestic adefovir dipivoxil" listed first

        However, the GSK drug has not yet listed, domestic enterprises have been The early bird catches. Ltd. - Tianjin Taipu pharmaceutical science and technology development in April 20th this year, two domestic enterprises and Tianjin Medicine Research Institute Pharmaceutical limited liability company has got the State Food and Drug Administration (SFDA) approval, production issued in May 14th, held a press conference in Beijing announced the domestic adefovir dipivoxil (brand name "daidin") a comprehensive listing of the GlaxoSmithKline announced in listing three months earlier. There is news that the beginning of June, in the national exclusive agent Hainan kangllian pharmaceutical began to the national hospital pharmacies and distribution.

        Chinese medicine "in the market price of 16 yuan per piece, slightly higher than the" He Puding "(15.8 yuan per piece), and He Weili (less than 21 yuan per piece), has advantages in price, plus the first on the market, Tianjin top to the drug market prospects with confidence. However, GSK is not a sign of weakness, the market manager Huang Yizheng said, "in the" operation in the market will Chinese full attack, covering high low-end market. Analysis of the industry, GlaxoSmithKline must achieve this point is not impossible, the reason is the previous lamivudine operation in Chinese market for many years, and mature market channels, the doctor education also has the outstanding advantages.

        Multinational pharmaceutical companies to snatch market B

        At the same time, several other multinational pharmaceutical companies more strength have also listed drug for hepatitis B drug market this huge cake. Roche R & D in May, the long-term interferon, "Luo Xin" has also been approved by the China food and drug administration, China's first to be used for the treatment of hepatitis B in the domestic long-term interferon. The United States Bristol Myers Squibb Company entecavir is expected at the end of the year or early next year listing. At present, in the country also held a press conference for market preheat.

        It is understood that in 2004 there are dozens of domestic production enterprises in the application of adefovir dipivoxil, and two or three have entered clinical trials, then quickly half a year can get production approval. These new drugs listed undoubtedly for GlaxoSmithKline market dominance has shaken effect.

Related links

        Comparison of several drugs

Efficacy: - interferon and nucleoside analogues can inhibit viral replication, but nucleoside analogues is difficult to completely remove the virus, but also interferon by regulating the body's immune function, to attack with hepatitis B virus liver cells, so the long-term efficacy of nucleoside analogues is better than.

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -.

- side effects: side effects of interferon alpha than nucleoside analogues; but nucleoside analogues could trigger the virus mutation, especially to lamivudine caused the virus mutation rate (the highest virus mutation occurred in 17% patients during the first year after the drug administration).

Price: for hepatitis B patients, do antiviral treatment of about 7000-10000 yuan per year; do domestic interferon treatment, a course of treatment (six months to a year) about 10000-20000 yuan.